8+ hour, 35+ min ago   (172+ words) aTyr Pharma updates FDA response timeline for efzofitimod Phase 3 study in pulmonary sarcoidosis, expected by mid-September 2026. Efzofitimod is being studied for the treatment of chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. aTyr Pharma anticipates receiving feedback from the FDA…...

2+ hour, 56+ min ago   (402+ words) Underwood criticizes Prime Healthcare’s closure plans, citing threats to maternal and pediatric care in Illinois. Underwood criticizes Prime Healthcare: Rep. Lauren Underwood said she met with Prime Healthcare leadership after reports that the company was ending inpatient pediatric services at…...

8+ hour, 52+ min ago   (394+ words) DelBene urges Congress to pass bipartisan legislation reducing prior authorization paperwork and improving seniors’ access to care. DelBene responds to insurer pledge: Rep. Suzan DelBene said UnitedHealthcare’s plan to reduce some prior authorization requirements is “encouraging,” but argued that voluntary…...

8+ hour, 52+ min ago   (373+ words) Bipartisan lawmakers introduced a bill limiting AI’s role in insurance denials, requiring doctor oversight and disclosure. Bill introduced on AI and insurance reviews: Four House lawmakers, including Tom Barrett, introduced the bipartisan Doctors Not AI Act. The proposal says artificial…...

10+ hour, 55+ min ago   (400+ words) Kean and bipartisan lawmakers introduced a bill to expand veterans’ and families’ access to Vet Center mental health counseling. Kean and colleagues introduce bill: Congressman Tom Kean Jr. said he introduced bipartisan legislation with Reps. Schrier, Fitzpatrick, Casten and Cohen…...

10+ hour, 55+ min ago   (375+ words) Mace proposes VA study and possible pilot program for peptide therapies for veterans' care, rehabilitation, pain, and mental health. Bill introduced for veterans’ peptide therapies: Rep. Nancy Mace said she introduced the “PEPTIDES for Veterans Act,” which would direct the…...

17+ hour, 35+ min ago   (152+ words) Clearmind Medicine Inc. begins Phase IIa trial for CMND-100 as a potential treatment for alcohol use disorder. The Phase IIa clinical trial for CMND-100 commenced on September 01, 2026. Currently, six patients have been enrolled in the ongoing Phase IIa clinical trial…...

1+ day, 17+ hour ago   (218+ words) BioVie Inc. completed the last visit in its bezisterim trial for Long COVID, with results expected by September 2026. The ADDRESS-LC trial is a Phase 2 study evaluating bezisterim for neurological symptoms related to Long COVID. The trial is fully funded by…...

1+ day, 5+ hour ago   (456+ words) Canada's Drug Agency recommends public reimbursement for LEQEMBI® in eligible Alzheimer’s patients, advancing access in Canada. LEQEMBI® is a monoclonal antibody designed to treat mild cognitive impairment or mild dementia due to Alzheimer’s disease. Canada’s Drug Agency (CDA-AMC) issued the…...

1+ day, 7+ hour ago   (437+ words) Disc Medicine will present clinical data for DISC-3405 and DISC-0974 at the SOHO Annual Meeting in September 2026. Disc Medicine, Inc. focuses on discovering and developing treatments for serious hematologic diseases. Disc Medicine will present clinical data at the SOHO Annual…...